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This retrospective study sought to systematically identify clinical and radiological features of
Mycobacterium kansasii and Mycobacterium simiae infections. The sample included consecu-
tive patients with a culture-positive diagnosis of M. simiae infection (nZ 102) or M. kansasii
infection (nZ 62) derived from the databases of the Laboratory of Microbiology of a tertiary
medical centre and two outpatient tuberculosis centres. Data on patient background and clin-
ical features were collected, and chest radiographs were analysed. Sixty percent of the
M. kansasii group were native born compared to 18% of the M. simiae group (pZ 0.0001).
M. simiae infection was associated with a higher rate of co-morbid disease, including diabetes
mellitus, heart disease, and malignancy. A similar rate of lung disease was found in both
groups. Clinical symptoms were significantly more common in patients with M. kansasii infec-
tion. On radiological study, M. kansasii infection was associated with more cavitations, and M.
simiae infection with more pulmonary infiltrates. Patients withM. simiae infection had a higher
likelihood of middle and lower lobe disease whereas patients with M. kansasii infection had
more upper lobe disease (pZ 0.001). Pleural effusions and lymphadenopathy were found only
in the presence of M. simiae infection. We concluded that there are major differences in the
epidemiologic features of M. kansasii and M. simiae infection which have important diagnostic
and therapeutic implications.
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M. kansasii versus M. simiae 1599Introduction Medical Center or attended one of two outpatient tubercu-Nontuberculous mycobacteria (NTM) were identified in
clinical specimens as early as 1885. With recent improve-
ments in techniques for the isolation and identification of
mycobacteria and the control of tuberculosis, the impor-
tance of NTM, especially in immunocompromised hosts, has
been recognised. Nevertheless, in contrast to the extensive
epidemiologic study of tuberculosis, temporal changes in
the epidemiology of NTM infections have hardly been
explored.
M. kansasii has traditionally been considered the most
virulent of the NTM.1,2 Infection by M. kansasii probably oc-
curs via an aerosol route.3e5 Tap water is a major reservoir
and the only environmental (water or soil) source of the
bacterium identified to date.6e9 However, the isolation of
M. kansasii from tap water can be intermittent, which
may explain why some investigators failed to recover it
from this source as well. Risk factors for M. kansasii infec-
tion include chronic lung disease, previous mycobacterial
disease, malignancy, and alcoholism.2,9e14 In immunocom-
petent patients, pulmonary disease is the most frequent
clinical manifestation,9 although approximately 40% have
no associated illness.2 When the infection is treated appro-
priately, outcome is good.
Isolates of M. simiae, another common NTM causing lung
disease.15 The frequency of isolation varies geographically,
with high reported rates in Cuba, the southwestern United
States, and Gaza, Israel.15,16 M. simiae isolates recovered
from humans are clinically relevant in an estimated
9e21% of specimens.16,17 They may present as a pulmonary
pathogen in patients with underlying pulmonary disease
and cause disseminated disease in patients with acquired
immune deficiency syndrome (AIDS).15e19 M. simiae is en-
demic to Israel, accounting for 30% of all NTM pathogens
isolated in the country in 1975e1981.15 Most cases were
considered environmental, most probably transmitted via
contaminated water.
The major clinical and therapeutic implications of in-
fection with these pathogens and their diverse magnitudes in
different countries warrant ongoing surveillance studies of
species distribution ofMycobacterium isolates. Furthermore,
although some authors have referred to clinical differences
between pulmonary M. kansasii and M. tuberculosis infec-
tions,3,15,16 to the best of our knowledge, there are no sys-
tematic studies comparing the clinical and radiological
features of M. kansasii and M. simiae pulmonary infections.
We chose to compare M. kansasii with M. simiae because
these two species are the most common NTM isolates in Israel
according to previous reports in Israel.17
The aim of the present study was to compare the clinical
features, radiological appearance and outcome of pulmo-
nary M. kansasii and M. simiae infection.
Patients and methods
Patients and setting
The sample included consecutive patients with a culture-
positive diagnosis of M. simiae infection (nZ 102) or
M. kansasii infection (nZ 62) who presented at Rabinlosis centres in Israel from April 1999 to April 2005. Rabin
Medical Center is a first-line and tertiary 900-bed facility
serving an urban population of 1,000,000. It includes de-
partments of medicine, neuro- and thoracic-surgery, oncol-
ogy, and haematology, a paediatric bone-marrow
transplantation unit, and a unit for solid organ transplanta-
tion. In all cases, the diagnosis of mycobacterial infection
was made by the hospital’s Laboratory of Microbiology ac-
cording to the guidelines of the American Thoracic Society
(ATS), as follows: appropriate symptomatology, compatible
radiographic abnormalities, and culture-positive respira-
tory specimens.16,17 Patients for whom there was a high
clinical suspicion of tuberculosis but negative sputum
smears underwent bronchoscopy with bronchoalveolar la-
vage and transbronchial biopsy to confirm the diagnosis.
Computed tomography (CT) was performed in all cases of
a suspected or confirmed abnormality on chest radiograph.
All patients were tested for human immunodeficiency
virus (HIV).
The study was approved by the Ethics Committee of
Rabin Medical Center.
Media
The solid LeJ medium (Heipha Diagnostika Biotest, Ger-
many) was applied to all specimens. The liquid medium
used during the first period consisted of 12B bottles
containing radio labelled Middlebrook 7H12 broth using
the Bactec 460TB (Becton Dickinson, USA) system. Before
use, the broth was supplemented with polymyxin B,
amphotericin B, nalidixic acid, trimethoprim and azlocillin
(PANTA). The liquid medium used during the second period
contained modified Middlebrook 7H9 broth base, supple-
mented with PANTA before use in the MGIT 960 Mycobac-
teria Growth Indicator Tube.
All media were inoculated in duplicate and incubated in
parallel at 30 C and 37 C for 8 weeks.
Identification of microorganisms
Isolates of acid-fast bacilli were identified as M. tuberculo-
sis, M. kansasii, or MAC by conventional biochemical
reactions1,2 and AccuProbe culture confirmation kits (Gen-
Probe, USA). M. simiae was identified by photochromoge-
nicity, positive niacin, negative nitrate reduction, and
Tween hydrolysis.
Data collection
Data on the clinical features of the patients (including
systemic co-morbid disease and smoking status), radiolog-
ical findings, and outcome were obtained from the case
notes and laboratory records by a single investigator.
Radiological assessment
Two radiologists who were blinded to the infecting organ-
ism and the clinical findings independently read the chest
radiographs taken within 2 weeks of diagnosis of mycobac-
terial disease.
1600 D. Shitrit et al.We also compared the previous CXR with the current CXR
in patients with radiological evidence of lung diseases from
the past.
The radiographs were assessed for the following fea-
tures: previous or co-existent lung disease, site of abnor-
mality, loss of lung volume, air space shadowing,
circumscribed opacities and cavitations, bronchopulmonary
spread, local pleural disease, pleural effusions, lymphade-
nopathy, and evidence of a primary focus.
Statistical analysis
Results are shown as mean SD. To analyse between-group
differences in categorical variables, chi-square test or
Fisher’s exact test was used, as appropriate. Pearson corre-
lation coefficient (r) and the significance for it (p) were
calculated between the variables. A p value of 0.05 or
less was considered statistically significant.
Results
Background characteristics
The baseline characteristics of the patients are shown in
Table 1. The mean age of the 62 patients with M. kansasii
infection was 44 18 (range 19e87) years; 21 (34%) were
women. The mean age of the 102 patients with infected
with M. simiae infection was 69 16 (range 51e85) yearsTable 1 Baseline characteristics, symptoms at presenta-
tion, and outcome in patients infected with M. kansasii or
M. simiae
M. kansasii,
nZ 62
M. simiae,
nZ 102
p
Value
Age (yr)a 44 18 69 16 0.001
Sex 0.001
Male 41 (66) 39 (38)
Female 21 (34) 63 (62)
Origin 0.0001
Israel 37 (60) 18 (18)
Former USSR 17 (28) 45 (44)
Ethiopia 4 (7) 4 (4)
Other 3 (5) 35 (35)
Smoking 26 (42) 38 (37) 0.634
Alcohol intake
14 units/week
4 (6.5) 4 (4) 0.358
Drug abuse 4 (6.5) 2 (2) 0.149
Symptoms at presentation
Chest pain 46 (74) 8 (8) 0.0001
Cough 53 (86) 14 (14) 0.0001
Haemoptysis 26 (42) 17 (17) 0.001
Weight loss 20 (32) 41 (34) 0.480
Sweat/fever 25 (40) 70 (58) 0.018
Hoarseness 2 (4) 0 (0) 0.114
Diagnosis by
bronchoscopy
8 (13) 14 (14) 0.483
Outcome, alive 62 (100) 97 (95) 0.147
All other values are n (%).
a Mean SD.and 63 (62%) were women. These differences were statisti-
cally significant (pZ 0.001).
Sixty percent of the patients in the M. kansasii group
were born in Israel (60%) and most of the remainder were
immigrants from the former USSR (28%), whereas in the
M. simiae group, most of the patients were immigrants
from the former USSR (44%) or other countries (39%). This
difference, too, was statistically significant (pZ 0.0001).
There were no significant differences between the
groups in drug or alcohol use or in smoking status.
Past and concurrent morbidities are shown in Table 2.
Significantly higher rates were noted in the M. simiae group
for diabetes mellitus (pZ 0.01), ischaemic heart disease
(pZ 0.002) and malignancy (pZ 0.04). The M. kansasii
group was characterised by a higher rate of chronic liver
disease (pZ 0.003). Only one patient (with M. kansasii in-
fection) was HIV-positive.
There were no significant between-group differences in
rates of associated lung disease, including bronchiectasis.
Previous tuberculosis had also similar rate in the M. simiae
group and in the M. kansasii group.
Presenting symptoms
The two groups showed significant differences in presenting
symptoms. M. kansasii infections were mostly symptom-
atic. Chest pain, cough and haemoptysis were all more
common in patients with M. kansasii infection than in pa-
tients with M. simiae infection. In contrast, sweat and fever
were more common in patients with M. simiae (Table 1).
Radiological features
M. kansasii infection had normal chest radiographs in six
patients (10%) and in 38 patients (37%) with M. simiae infec-
tion (pZ 0.0001). However, most of these patients (34 pa-
tients) had hyperinflation, oligaemia and chronic lung
changes in the base of the lungs. Most of them were asymp-
tomatic. All remaining patients with abnormal CXR had
symptoms of mycobacterial disease.
The anatomic distribution of the radiological findings
differed between the groups (Table 3). Upper lobe disease
was diagnosed in 50 patients (80%) with M. kansasiiTable 2 Past and present medical problems in patients
infected with M. kansasii or M. simiae
M. kansasii,
nZ 62
M. simiae,
nZ 102
p Value
HIV 1 (1.6) 0 0.378
Chronic liver disease 10 (16) 3 (3) 0.003
Diabetes 8 (13) 30 (29) 0.01
Cardiac disease 5 (8) 28 (28) 0.002
Malignancy 3 (5) 15 (15) 0.04
Previous tuberculosis 7 (11) 18 (15) 0.335
Chronic obstructive
pulmonary disease
22 (36) 38 (37) 0.477
Bronchiectasis 8 (13) 19 (19) 0.231
Use of immunosuppressive
medication
8 (13) 31 (31) 0.394
Table 3 Radiological findings in patients infected with
M. kansasii or M. simiae
M. kansasii,
nZ 62
M. simiae,
nZ 102
p Value
Normal chest X-ray 6 (10) 38 (37) 0.0001
Infiltrates 21 (34) 58 (57) 0.01
Cavitation 35 (57) 3 (3) 0.001
Location in chest X-ray
Right upper lobe 30 (48) 15 (25)
Left upper lobe 20 (32) 12 (20) 0.001
Lower/middle lobes 4 (6.5) 33 (55)
Bilateral disease 7 (11) 4 (4) 0.075
Pleural effusion 0 16 (16) 0.0001
Lymphadenopathy 0 3 (3) 0.001
Miliary pattern 0 0 (0)
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fection (pZ 0.001). By contrast, most of the patients (55%)
with M. simiae infection had pulmonary infiltrates in the
lower- and middle-zones. A right-side predominance was
noted in association with M. kansasii infection (48% of
patients).
Other radiological findings are presented in Table 3.
Pleural effusions were seen in 16 patients (16%) with M.
simiae infection and in none of the patients with M. kansa-
sii infection (pZ 0.0001). In four patients (4%), the effu-
sion was the only abnormality present. Lymphadenopathy
was noted in three patients (3%), all from the M. simiae
group. Cavitary disease was noted in 35 patients (57%)
with M. kansasii infection and only three patients (3%)
with M. simiae infection (pZ 0.001).
Treatment
All our patients treated with the regimen of rifampicin
(600 mg), ethambutol (25 mg/kg for the first 2 months, then
15 mg/kg) and clarithromycin (1000 mg/day) given daily for
at least 12 months of negative sputum cultures according to
the ATS criteria.
Outcome
The duration of follow-up ranged from 28 to 108 months
(mean 39 months) for the M. kansasii group and from 44 to
105 months (mean 24 months) for the M. simiae group. No
relapses were detected during the follow-up period in either
group. There were no deaths in the M. kansasii group. Five
patients in the M. simiae group died, but none of the deaths
was directly related to the mycobacterial disease (three
were due to cerebral stroke and two to cardiac disease).
Discussion
The present study is the largest so far to directly and
systematically compare the clinical and radiologic features
of M. kansasii and M. simiae infections. Our findings re-
vealed important differences, making it possible to reliably
differentiate between these two diseases on clinical
grounds.4,15Diabetes, cardiac disease, and malignancy were rare in
the M. kansasii group, whereas associated lung disease, es-
pecially chronic obstructive pulmonary disease, and chronic
liver disease were more common in the M. kansasii group
than in the M. simiae group.
Regarding symptoms, chest pain, cough and haemoptysis
were all more common in the M. kansasii group, and sweat
and fever were more common in the M. simiae group. This
finding is consistent with the statement of the American
Thoracic Society that symptoms are more common in lung
disease caused by NTM than in other NTM infections.20
Most of the patients in both groups in our series were
Caucasian (88% and 62%, respectively), either native Israelis
or immigrants from the former USSR. These findings suggest
that NTM infection may be less common in the non-white
population. However, by group, native Israelis accounted
for a significantly smaller proportion of the patients with
M. simiae infection than M. kansasii infection (18% versus
60%, pZ 0.0001).
Haemoptysis occurred in 42% of the M. kansasii group,
which is slightly higher than the 20e30% rates reported in
earlier studies.20e22 Haemoptysis in pulmonary infections
may be related to the degree of endobronchial disease
and the erosion of bronchial vessels by cavitation. Although
there are no available data on the relative incidence of en-
dobronchial disease, the reported incidence of cavitation in
M. kansasii infection is 57%,4,23e25 which is close to our hae-
moptysis rate. It is noteworthy that cavitations were much
less common in M. simiae infections.
Although many previous studies emphasised the higher
rate of pre-existing lung disease, particularly tuberculosis,
in pulmonary NTM infection compared to M. tuberculosis in-
fection,3,20 none of them used a controlled comparison de-
sign. In our series, there was a higher incidence of history of
tuberculosis in the M. simiae group than the M. kansasii
group (Table 2).
In Israel, most cases of HIV are identified in immigrants,
and not in the native-born population. We found only one
case of HIV infection in the M. kansasii group, and no cases
in the M. simiae group. The relatively low incidence of HIV
infection and AIDS in Israel may account for these low
rates.
The radiographic features of NTM pulmonary infections
have been variably reported to be indistinguishable from
tuberculosis,26e28 highly suggestive of NTM infection,28e30or
quite different from M. tuberculosis infection.31,32 These
discrepanciesmay be explained in part by the different diag-
nostic methods used. Our study is the first matched compar-
ison of the radiological features ofM. kansasii andM. simiae
infection, and our radiologists were blinded to the clinical
data and the infecting organism. Our findings yielded several
noteworthy differences. As noted above, M. kansasii
infectionwas associatedwith cavitary infiltrates and a predi-
lection for upper lobe disease whereas M. simiae infection
was associated with noncavitary disease and a lower-
middle-lobe predominance. It should be borne in mind that
others have recognised noncavitary lung disease as part of
the spectrum of M. kansasii infection,4,9 and that in our
series, cavitary disease occurred in only 57% of theM. kansa-
sii group compared to 3% of the M. simiae group.
Although the radiographic picture of M. kansasii infec-
tions was not pathognomonic, the disease usually occurred
1602 D. Shitrit et al.unilaterally without a pleural component or lymphadenop-
athy. In accordance with the literature on NTM,21,24 pleural
effusions were not noted in any patient in our M. kansasii
group compared to 16% of the M. simiae group.
In CHF and cardiac disease the pleural effusion in most
of the cases are bilateral with transudate characteristics. In
all cases of pleural effusion due to M. simiae there were
unilateral pleural effusions. In addition, none of the pa-
tients with malignancy had pleural effusion.
We also compared all CXRs with the previous CXRs in
patients with co-morbid disease.
The similar high survival in the M. kansasii and M. simiae
groups (100% and 95%, respectively) may be attributable to
the low rate of extensive disease and the early mycobacte-
rial treatment. None of the deaths that occurred were di-
rectly due to the NTM disease. These data support the
application of early treatment regimens in NTM infection.
All cases treated with combination of rifampicin, eth-
ambutol and clarithromycin. We treated only patients
according to the ATS criteria. Most of the data from US
about the treatment of kansasii and simiae are from pa-
tients with HIV and mycobacterial disease. Most of these
patients had severe lung disease and reduced outcome.
As best we know, there is no study about the genotype of
the M. simiae isolates. In addition, there is no data con-
cerning M. simiae disease in Eastern Europe and Ethiopia.
Our study has several limitations: retrospective design;
use of medical records for data collection; and radiological
assessment based mainly on chest radiographs and not CT
scans. Further, larger prospective studies are needed to
corroborate our findings.
Summary
There are some significant differences in the clinical and
radiological appearance of M. kansasii and M. simiae infec-
tions. Findings of lower- and middle-lobe disease, pleural
effusions, or mediastinal lymphadenopathy make the diag-
nosis of M. kansasii infection very unlikely. M. simiae infec-
tion appears to occur more often in immigrants and is
associated with a lower rate of fever and night sweats at
presentation than M. kansasii infection. The outcome of
both mycobacterial infections is excellent. These differ-
ences are important for diagnosis and in decisions regarding
early empirical antimycobacterial therapy. Continuous sur-
veys of mycobacterial species and analyses of the clinical
significance of these differences are warranted.
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